Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16094592 | 0.84 | LMNA (0.46) | LMNASLC29A1GAACYP1A2CYP2C19 | |
| SCHEMBL20179382 | 0.83 | CDK2 (0.36) | — | |
| SCHEMBL20164346 | 0.83 | SLC29A1 (0.36) | LMNASLC29A1GAACYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL17494523 | 0.82 | LMNA (0.45) | LMNASLC29A1GAACYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL20164312 | 0.81 | SLC29A1 (0.35) | LMNASLC29A1GAACYP1A2CYP2C19 | |
| SCHEMBL16094989 | 0.79 | ESR1 (0.50) | SLC29A1ESR1 | |
| Hydrochloric Acid SCHEMBL16094532 | 0.78 | ESR1 (0.48) | SLC29A1ESR1 | |
| SCHEMBL20179360 | 0.73 | SLC29A1 (0.61) | LMNASLC29A1CYP1A2CYP2C19 | |
| SCHEMBL20164392 | 0.73 | CDK2 (0.42) | LMNASLC29A1GAAL3MBTL1 | |
| SCHEMBL20164663 | 0.73 | CDK2 (0.42) | LMNASLC29A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | LMNA 1394/4885SLC29A1 4472/4885GAA 1936/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | LMNA 1200/4885SLC29A1 4518/4885GAA 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.